What it sells
Authoring documents for life sciences in minutes, not months.
Business model breakdown
Buyer: who owns the budget?
UnverifiedRegulatory and medical writing teams at biopharma companies.
Trigger: what makes them buy now?
Need to produce INDs, NDAs and BLAs and their component documents faster and more cheaply.
Workflow: what inputs become what output?
Generate first drafts of regulatory documents (clinical study reports, clinical/non-clinical overviews, summaries, IBs) from source data using purpose-built AI and templates, regenerate sections, track data across documents, then publish.
Distribution: how it reaches customers
Demo-led ("Book Demo"), events and community.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Winter 2024 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.